Stocks
Versartis, Inc.VSAR
YHDHealthcareBiotechnology$1.19-2.52%
Price as of · delayed, not real-time
Previously a clinical-stage biopharmaceutical company, Versartis focused on developing treatments for endocrine diseases, including growth hormone deficiency. The company ceased operations after its lead candidate failed to meet primary endpoints in a Phase 3 trial, resulting in its delisting.
Market Cap: $052W Range: $1.14-$2.75
Congressional Interest in Versartis, Inc. (VSAR)
1 member of Congress has disclosed 1 trade in Versartis, Inc. (VSAR), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
1
Sells
0
Who in Congress Is Trading VSAR?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2017-03-22 | BOB GIBBS | buy | $1K-$15K |